Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2022 08:30 ET | Source: Celsion Corporation

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting

Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR Annual Meeting LAWRENCEVILLE, N.J., April 14, 2022 (GLOBE NEWSWIRE) --...
February 17, 2022 08:30 ET | Source: Celsion Corporation

Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

OVATION 2 Study is Over 75% Enrolled; Full Enrollment Expected by Mid-2022 Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over...